Summary
Regeneron Pharmaceuticals, Inc. (REGN) has filed a Form 8-K on January 29, 2026, to announce its financial and operating results for the fourth quarter and full year ended December 31, 2025. The press release detailing these results is attached as Exhibit 99.1 and is incorporated by reference. Investors should refer to this press release for specific figures related to revenue, profitability, and operational performance. This filing is crucial for understanding the company's recent financial health and its trajectory heading into the new fiscal year. The information is being furnished and not deemed 'filed' under Section 18 of the Securities Exchange Act of 1934, meaning it does not automatically update previous SEC filings. Investors should consult the press release directly for comprehensive details.
Key Highlights
- 1Regeneron announced fourth quarter and full year 2025 financial and operating results.
- 2The detailed results are provided in a press release furnished as Exhibit 99.1.
- 3The event date for the announcement was January 29, 2026, with the filing occurring on January 29, 2026.
- 4This report serves as a key disclosure mechanism for the company's performance updates.
- 5Investors are directed to Exhibit 99.1 for specific financial and operational data.
- 6The information is furnished under Item 2.02 and is not considered 'filed' for certain regulatory purposes.